ALZN
Alzamend Neuro, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.66
−2.35%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -97.2%
- EBIT
- -95.0%
- EPS
- +84.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +69.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -94.7%
- EBIT
- -95.0%
- Net income
- -94.3%
- EPS
- +76.8%
- Free cash flow
- -17.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026